Tag Archives: HER2 minus breast cancer
Ribociclib plus Endocrine Therapy demonstrated improved overall survival in advanced HR+/HER2- Breast Cancer
According to findings from an exploratory analysis of the Phase-III MONALEESA-7 trial presented during the 2021 ESMO Breast Cancer Virtual […]
